| Literature DB >> 28673758 |
Claire McGregor1, Alexander Riordan2, Janice Thornton2.
Abstract
Schizophrenia is a complex neuropsychiatric illness with marked sex differences. Women have later onset and lesser symptoms, which has led to the hypothesis that estrogens are protective in schizophrenia. Cognitive dysfunction is a hallmark of the disease and the symptom most correlated with functional outcome. Here we describe a number of mechanisms by which estrogens may be therapeutic in schizophrenia, with a focus on cognitive symptoms. We review the relationship between estrogens and brain derived neurotrophic factor, neuroinflammation, NMDA receptors, GABA receptors, and luteinizing hormone. Exploring these pathways may enable novel treatments for schizophrenia and a greater understanding of this devastating disease.Entities:
Keywords: BDNF; Cognitive deficits; Estrogen; GABA; Luteinizing hormone; NMDA receptor hypofunction; Neuroinflammation; Neuroprotection; Schizophrenia
Mesh:
Substances:
Year: 2017 PMID: 28673758 DOI: 10.1016/j.yfrne.2017.06.003
Source DB: PubMed Journal: Front Neuroendocrinol ISSN: 0091-3022 Impact factor: 8.606